Crispr Therapeutics call volume above normal and directionally bullish
Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,734 calls trading, 1.3x expected, and implied vol increasing almost 4 points ...
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...
Nasdaq4d
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...
Crispr Therapeutics AG: Strategic Pipeline Progress and Financial Strength Drive Buy Rating
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...